Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2012

View Archived Issues

New PAK-4 inhibitor under development to treat gastric cancers

Scientists discover novel neurotrophic drug to treat cognitive decline

Findings presented from two phase III trials of Lu-AA-21004 in GAD

Kinetin shows promise to treat familial dysautonomia

Astellas Pharma presents new drug for treatment of transplant rejection

Toray divulges new inhibitors of 11-beta-HSD1

New camptothecin derivatives designed in Spain

IntraCellular Therapies claims novel phosphodiesterase 1B inhibitors

Novel phosphodiesterase inhibitors disclosed

New monoglyceride lipase inhibitors prepared by Sanofi

Syndax Pharmaceuticals designs new azacitidine prodrugs

Roche presents novel drugs for Parkinson's disease

FDA advisory committee to review Xgeva sBLA

Apricus Biosciences finalizes acquisition

BG Medicine files application for second cardiovascular diagnostic test

Marshall Edwards raises funds to advance lead oncology candidates

Opko Health completes acquisition

Symmetry Medical acquires surgical instruments business

Amgen moves AMG-172 to clinic

MethylGene recruiting participants in phase II MGCD-290 study

Gene therapy for wet AMD enters phase I/II testing

Clinical trial application submitted in Russia for AT-001

Clinical development ZP-1846 advances

FDA expands indication of Prevnar 13

Prima BioMed provides update on preclinical testing of Cripto-1 immunotherapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...